{"entity":{"id":"paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013","kind":"paper","name":"CONKO-001: adjuvant gemcitabine and long-term outcomes after resected pancreatic cancer","aka":[],"tldr":"Six months of gemcitabine after complete removal of pancreatic cancer doubled the time to relapse and roughly doubled five-year survival, from 10 to 21 percent, in the trial that established adjuvant chemotherapy for the disease.","summary":"Long-term report of the German and Austrian open-label phase 3 CONKO-001 trial: 368 patients randomised between 1998 and 2004 to six months of adjuvant gemcitabine or observation, 354 analysed by intention to treat, median follow-up 136 months.\n\nMedian disease-free survival was 13.4 months with gemcitabine against 6.7 months with observation (hazard ratio 0.55); overall survival was improved (hazard ratio 0.76, p 0.01), with five-year survival 20.7 against 10.4 percent and ten-year survival 12.2 against 7.7 percent.","asOf":"2026-09-22","links":[{"label":"JAMA 2013","url":"https://doi.org/10.1001/jama.2013.279201"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24104372/"}],"tags":[],"related":[],"cancers":["resectable-pdac","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["conko-001"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jama"],"dependsOn":[],"notes":[],"journal":"JAMA","year":2013,"doi":"10.1001/jama.2013.279201","pmid":"24104372","authors":"Oettle H, Neuhaus P, Hochhaus A, et al.","paperType":"rct","findings":["Median disease-free survival 13.4 months (95% CI 11.6 to 15.3) versus 6.7 months (6.0 to 7.5); hazard ratio 0.55 (0.44 to 0.69), p < 0.001.","Overall survival hazard ratio 0.76 (0.61 to 0.95), p 0.01; five-year survival 20.7 versus 10.4 percent; ten-year survival 12.2 versus 7.7 percent."],"whatItMeans":"Adjuvant chemotherapy is standard after pancreatic cancer resection; gemcitabine alone remains the option for patients who cannot tolerate combinations.","caveats":["Later methodological critiques raised concerns about randomisation and surgical standardisation.","Registered with ISRCTN only (ISRCTN34802808)."],"changedPractice":true,"participants":368},"route":"/key-papers/paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"trial":[{"id":"conko-001","kind":"trial","name":"CONKO-001","route":"/trials/conko-001/"}],"journal":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/"}]}}